Drugs & Targets Tempus AI, Stemline Therapeutics collaborate to enhance ESR1 testing in breast cancer February 28, 2025Vol.51 No.08
Drugs & Targets DeepHealth, TeraRecon announce collaboration around integrated AI and advanced visualization February 28, 2025Vol.51 No.08
Drugs & Targets FDA grants priority review to Boehringer’s BI 1810631 for the treatment of HER2-mutant advanced NSCLC February 21, 2025Vol.51 No.07
Drugs & Targets FDA approves Adcetris + lenalidomide + rituximab for r/r large B-cell lymphoma February 14, 2025Vol.51 No.06
Drugs & Targets FDA approves Gomekli for pediatric patients with neurofiromatosis type 1 February 14, 2025Vol.51 No.06
Drugs & Targets EC grants marketing authorization for Removab as a treatment for malignant ascites February 14, 2025Vol.51 No.06
Drugs & Targets Moffitt, 1ST Biotherapeutics collaborate to advance immuno-oncology February 14, 2025Vol.51 No.06
Drugs & Targets FDA grants orphan drug designation to MB-105 for CD5-targeted CAR T-cell therapy February 07, 2025Vol.51 No.05
Drugs & Targets CHMP recommends approval of Opdivo + Yervoy for unresectable or advanced HCC February 07, 2025Vol.51 No.05
Drugs & Targets CHMP recommends approval Breyanzi for r/r follicular lymphoma February 07, 2025Vol.51 No.05
